Skip to main content

A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.

Publication ,  Journal Article
Hunter, DJ; Losina, E; Guermazi, A; Burstein, D; Lassere, MN; Kraus, V
Published in: Curr Drug Targets
May 2010

This narrative review outlines the work done in other fields with regards biomarker validation and qualification and the lessons that we may learn from this experience. Defining a universally agreed upon path for biomarker validation and qualification is urgently needed to circumvent many of the hurdles faced in OA therapeutic development irrespective of whether we are discussing biochemical markers, imaging markers or other measures. This review proposes a path that may be suitable for osteoarthritis and poses some logical next steps that will take us in this direction.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Drug Targets

DOI

EISSN

1873-5592

Publication Date

May 2010

Volume

11

Issue

5

Start / End Page

536 / 545

Location

United Arab Emirates

Related Subject Headings

  • Validation Studies as Topic
  • Treatment Outcome
  • Pharmacology & Pharmacy
  • Osteoarthritis
  • Models, Organizational
  • Humans
  • Drug and Narcotic Control
  • Drug Discovery
  • Clinical Trials as Topic
  • Biomarkers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hunter, D. J., Losina, E., Guermazi, A., Burstein, D., Lassere, M. N., & Kraus, V. (2010). A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr Drug Targets, 11(5), 536–545. https://doi.org/10.2174/138945010791011947
Hunter, David J., Elena Losina, Ali Guermazi, Deb Burstein, Marissa N. Lassere, and Virginia Kraus. “A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.Curr Drug Targets 11, no. 5 (May 2010): 536–45. https://doi.org/10.2174/138945010791011947.
Hunter DJ, Losina E, Guermazi A, Burstein D, Lassere MN, Kraus V. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr Drug Targets. 2010 May;11(5):536–45.
Hunter, David J., et al. “A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.Curr Drug Targets, vol. 11, no. 5, May 2010, pp. 536–45. Pubmed, doi:10.2174/138945010791011947.
Hunter DJ, Losina E, Guermazi A, Burstein D, Lassere MN, Kraus V. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr Drug Targets. 2010 May;11(5):536–545.

Published In

Curr Drug Targets

DOI

EISSN

1873-5592

Publication Date

May 2010

Volume

11

Issue

5

Start / End Page

536 / 545

Location

United Arab Emirates

Related Subject Headings

  • Validation Studies as Topic
  • Treatment Outcome
  • Pharmacology & Pharmacy
  • Osteoarthritis
  • Models, Organizational
  • Humans
  • Drug and Narcotic Control
  • Drug Discovery
  • Clinical Trials as Topic
  • Biomarkers